EYPT

SEC source: 0000899243-18-009028 · doc4.xml · nonDerivative · entry 2

EW Healthcare Partners, L.P. · CIK 0001612343 · 10% owner

EW Healthcare Partners-A, L.P. · CIK 0001736240 · 10% owner

Essex Woodlands Fund IX-GP, L.P. · CIK 0001652285 · 10% owner

Essex Woodlands IX, LLC · CIK 0001652286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · EW Healthcare Partners-A L.P.

Disclosed balance after: 8,606,324

F1 · balance_after: Includes 8,273,461 shares held by EW Healthcare Partners L.P. ("EWHP") and 332,863 shares held by EW Healthcare Partners-A L.P. ("EWHP-A"). Essex Woodlands Fund IX-GP, L.P. ("Fund IX-GP") is the general partner of EWHP and EWHP-A, respectively. Essex Woodlands IX, LLC (the "General Partner") is the general partner of Fund IX-GP. The General Partner holds sole voting and dispositive power over the shares held by EWHP and EWHP-A. The managers of the General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman (also a member of the Issuer's board of directors), Petri Vainio and Steve Wiggins (collectively, the "Managers"), and may exercise voting and investment control over the shares only by the majority action of the Managers.

F1 · ownership.direct: Includes 8,273,461 shares held by EW Healthcare Partners L.P. ("EWHP") and 332,863 shares held by EW Healthcare Partners-A L.P. ("EWHP-A"). Essex Woodlands Fund IX-GP, L.P. ("Fund IX-GP") is the general partner of EWHP and EWHP-A, respectively. Essex Woodlands IX, LLC (the "General Partner") is the general partner of Fund IX-GP. The General Partner holds sole voting and dispositive power over the shares held by EWHP and EWHP-A. The managers of the General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman (also a member of the Issuer's board of directors), Petri Vainio and Steve Wiggins (collectively, the "Managers"), and may exercise voting and investment control over the shares only by the majority action of the Managers.

SEC source: 0000899243-18-009028 · doc4.xml · nonDerivative · entry 1

EW Healthcare Partners, L.P. · CIK 0001612343 · 10% owner

EW Healthcare Partners-A, L.P. · CIK 0001736240 · 10% owner

Essex Woodlands Fund IX-GP, L.P. · CIK 0001652285 · 10% owner

Essex Woodlands IX, LLC · CIK 0001652286 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,606,324

F1 · balance_after: Includes 8,273,461 shares held by EW Healthcare Partners L.P. ("EWHP") and 332,863 shares held by EW Healthcare Partners-A L.P. ("EWHP-A"). Essex Woodlands Fund IX-GP, L.P. ("Fund IX-GP") is the general partner of EWHP and EWHP-A, respectively. Essex Woodlands IX, LLC (the "General Partner") is the general partner of Fund IX-GP. The General Partner holds sole voting and dispositive power over the shares held by EWHP and EWHP-A. The managers of the General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman (also a member of the Issuer's board of directors), Petri Vainio and Steve Wiggins (collectively, the "Managers"), and may exercise voting and investment control over the shares only by the majority action of the Managers.

F1 · ownership.direct: Includes 8,273,461 shares held by EW Healthcare Partners L.P. ("EWHP") and 332,863 shares held by EW Healthcare Partners-A L.P. ("EWHP-A"). Essex Woodlands Fund IX-GP, L.P. ("Fund IX-GP") is the general partner of EWHP and EWHP-A, respectively. Essex Woodlands IX, LLC (the "General Partner") is the general partner of Fund IX-GP. The General Partner holds sole voting and dispositive power over the shares held by EWHP and EWHP-A. The managers of the General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman (also a member of the Issuer's board of directors), Petri Vainio and Steve Wiggins (collectively, the "Managers"), and may exercise voting and investment control over the shares only by the majority action of the Managers.

SEC source: 0000899243-18-008243 · doc4.xml · nonDerivative · entry 1

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · shares: On March 19, 2018 (the "NDA Acceptance Date"), the U.S. Food and Drug Administration ("FDA") accepted pSivida Corp.'s (the "Company") new drug application for Durasert 3-year treatment for posterior segment uveitis. As a result, 5,000 shares representing a previously granted performance stock unit award vested on that date. An additional 5,000 shares from this award will vest on the first anniversary of the NDA Acceptance Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.

SEC source: 0000899243-18-008244 · doc4.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,033

F1 · shares: On March 19, 2018 (the "NDA Acceptance Date"), the U.S. Food and Drug Administration ("FDA") accepted pSivida Corp.'s (the "Company") new drug application for Durasert 3-year treatment for posterior segment uveitis. As a result, 19,166 shares representing a previously granted performance stock unit award vested on that date. An additional 19,167 shares from this award will vest on the first anniversary of the NDA Acceptance Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.

SEC source: 0000899243-18-008245 · doc4.xml · nonDerivative · entry 1

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,333

F1 · shares: On March 19, 2018 (the "NDA Acceptance Date"), the U.S. Food and Drug Administration ("FDA") accepted pSivida Corp.'s (the "Company") new drug application for Durasert 3-year treatment for posterior segment uveitis. As a result, 4,166 shares representing a previously granted performance stock unit award vested on that date. An additional 4,167 shares from this award will vest on the first anniversary of the NDA Acceptance Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.

SEC source: 0000899243-17-029611 · doc4.xml · derivative · entry 1

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,892

Underlying: Common Stock · 62,892 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

F2 · derivative.exercise_date: The restricted stock units will vest in full on December 22, 2018 and the vested shares will be delivered to the reporting person within 30 days following the vesting date.

F2 · derivative.expiration_date: The restricted stock units will vest in full on December 22, 2018 and the vested shares will be delivered to the reporting person within 30 days following the vesting date.

SEC source: 0000899243-17-029156 · doc4.xml · derivative · entry 1

Peterson Kristine · CIK 0001508596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2027-06-27

F1 · derivative.exercise_date: The option becomes exercisable in three equal annual installments beginning on June 27, 2018.

SEC source: 0000899243-17-029169 · doc4.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2027-06-27

F3 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning June 27, 2018.

SEC source: 0000899243-17-029169 · doc4.xml · derivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

SEC source: 0000899243-17-029161 · doc4.xml · derivative · entry 2

Godshall Douglas Evan · CIK 0001404227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of pSivida Corp. (the "Company").

F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-17-029161 · doc4.xml · derivative · entry 1

Godshall Douglas Evan · CIK 0001404227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2027-06-27

SEC source: 0000899243-17-029160 · doc4.xml · derivative · entry 2

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of pSivida Corp. (the "Company").

F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-17-029160 · doc4.xml · derivative · entry 1

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2027-06-27

SEC source: 0000899243-17-029159 · doc4.xml · derivative · entry 2

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of pSivida Corp. (the "Company").

F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-17-029159 · doc4.xml · derivative · entry 1

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2027-06-27

SEC source: 0000899243-17-029153 · doc4.xml · derivative · entry 2

Barry James J · CIK 0001541253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of pSivida Corp. (the "Company").

F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-17-029153 · doc4.xml · derivative · entry 1

Barry James J · CIK 0001541253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2027-06-27

SEC source: 0000899243-17-029147 · doc4.xml · derivative · entry 2

Duker Jay S. · CIK 0001630864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of pSivida Corp. (the "Company").

F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

SEC source: 0000899243-17-029147 · doc4.xml · derivative · entry 1

Duker Jay S. · CIK 0001630864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2027-06-27

SEC source: 0000899243-17-017517 · doc4.xml · derivative · entry 2

JORN DEBORA · CIK 0001643304 · EVP, Corp. & Comm'l Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2027-06-27

F3 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning June 27, 2018.

SEC source: 0000899243-17-017517 · doc4.xml · derivative · entry 1

JORN DEBORA · CIK 0001643304 · EVP, Corp. & Comm'l Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

SEC source: 0000899243-17-017515 · doc4.xml · derivative · entry 2

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2027-06-27

F3 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning June 27, 2018.

SEC source: 0000899243-17-017515 · doc4.xml · derivative · entry 1

Ross Leonard S · CIK 0001458753 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

SEC source: 0000899243-17-017520 · doc4.xml · derivative · entry 2

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2027-06-27

F3 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning June 27, 2018.

SEC source: 0000899243-17-017520 · doc4.xml · derivative · entry 1

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

SEC source: 0000899243-17-016365 · doc4.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,700

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.72 to $1.80. The reporting person undertakes to provide pSivida Corp., any security holder of pSivida Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000899243-16-035515 · doc4.xml · derivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 850,000

Underlying: Common Stock · 850,000 shares

Expires 2026-09-15

F1 · derivative.exercise_date: The option becomes exercisable in four equal annual installments beginning on September 15, 2017.

SEC source: 0000899243-16-035514 · doc4.xml · derivative · entry 1

Godshall Douglas Evan · CIK 0001404227 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2026-07-21

SEC source: 0000899243-16-035517 · doc4.xml · derivative · entry 1

ROGERS MICHAEL W · CIK 0001244159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2026-07-21

SEC source: 0000899243-16-035519 · doc4.xml · derivative · entry 1

Barry James J · CIK 0001541253 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2026-07-21

SEC source: 0000899243-16-035512 · doc4.xml · derivative · entry 1

Duker Jay S. · CIK 0001630864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2026-09-26

F1 · derivative.exercise_date: The option becomes exercisable in three equal annual installments beginning on September 26, 2017.

SEC source: 0000899243-16-035511 · doc4.xml · derivative · entry 1

Mazzo David J · CIK 0001334549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2026-07-21

SEC source: 0000904454-16-001542 · edgar.xml · derivative · entry 1

JORN DEBORA · CIK 0001643304 · EVP, Corp. & Comm'l Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2026-11-02

F1 · derivative.exercise_date: Options to purchase 75,000 shares shall vest and become exercisable on each of the first, second, third and fourth anniversaries, respectively, of the date of grant.